Drug General Information (ID: DDIJXHF34N)
Drug Name			Pasireotide		Drug Info		Copper oxodotreotide Cu-64		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Somatostatin/Somatostatin Analogs				Diagnostic Radiopharmaceuticals

Mechanism of Pasireotide-Copper oxodotreotide Cu-64 Interaction (Severity Level: Major)
Interference of cell/tissue uptake Click to Show/Hide Mechanism Graph
Drug Name		Pasireotide				Copper oxodotreotide Cu-64
Mechanism		Somatostatin analog				Affects somatostatin analog diagnostic test results
Key Mechanism Factor 1
		Factor Name		Pharmacokinetics
		Factor Description		Alters the distribution of the drug, leading to changes in the plasma concentration of the drug and affecting the pharmacological effects.
Mechanism Description		Interference of cell/tissue uptake of Pasireotide by Copper oxodotreotide Cu-64

Recommended Action
Management		PET imaging with copper Cu 64 dotatate should be performed prior to dosing with somatostatin analogs. For patients receiving short-acting somatostatin analogs, a washout period of 2 days is recommended prior to imaging. For patients receiving long-acting somatostatin analogs, a washout period of 28 days is recommended prior to imaging.

References
1	Product Information. Detectnet (copper cu 64 dotatate). Currax Pharmaceuticals LLC, Morristown, NJ.